(Boursier.com) — Sanofi et Teva Pharmaceuticals, filiale américaine de Teva Pharmaceutical Industries Ltd., ont présenté de ...

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Investing.com -- Le médicament rilzabrutinib, développé par Sanofi US Services Inc., a reçu la désignation de médicament orphelin le 20/02/2025 par la FDA pour le traitement de l'anémie hémolytique ...

Sanofi Healthcare India receives marketing authorization for Rezurock, a new treatment for chronic graft-versus-host disease ...

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

Cette opération, qui avait suscité de vives inquiétudes lorsqu’elle avait été annoncée en octobre, entrera en vigueur «au ...

Sanofi Healthcare India receives marketing authorization for Rezurock (Belumosudil), a new treatment for Chronic Graft-versus-Host Disease (cGVHD) in adults and adolescents.

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been accepted for priority review by the US Food and Drug Administration (FDA ...

Paris: Sanofi and CD&R have announced that they have signed the share purchase agreement in relation to the sale of a 50 ...

The Indian subsidiary of French pharma major Sanofi has received marketing authorization for Rezurock (belumosudil tablets) in India.